# Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma

> **NCT05030077** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Second Hospital** · enrollment: 53 (estimated)

## Conditions studied

- Urothelial Carcinoma
- Anlotinib
- Urogenital Neoplasms
- Cisplatin
- Carboplatin
- Gemcitabine
- Antineoplastic Agents

## Interventions

- **DRUG:** Anlotinib
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT05030077
- **Lead sponsor:** Tianjin Medical University Second Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-01
- **Primary completion:** 2023-09-01
- **Final completion:** 2024-09-01
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2021-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05030077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05030077, "Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05030077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*